GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Beneish M-Score

Concord Biotech (BOM:543960) Beneish M-Score : -2.18 (As of Apr. 08, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.18 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Concord Biotech's Beneish M-Score or its related term are showing as below:

BOM:543960' s Beneish M-Score Range Over the Past 10 Years
Min: -2.48   Med: -2.18   Max: -2.13
Current: -2.18

During the past 5 years, the highest Beneish M-Score of Concord Biotech was -2.13. The lowest was -2.48. And the median was -2.18.


Concord Biotech Beneish M-Score Historical Data

The historical data trend for Concord Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Beneish M-Score Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
- - -2.13 -2.48 -2.18

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.18 - - -

Competitive Comparison of Concord Biotech's Beneish M-Score

For the Biotechnology subindustry, Concord Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Biotech's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Beneish M-Score falls into.


;
;

Concord Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Concord Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9826+0.528 * 1.0064+0.404 * 0.7702+0.892 * 1.2016+0.115 * 1.0335
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0765+4.679 * 0.02507-0.327 * 0.6468
=-2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ₹3,685 Mil.
Revenue was ₹9,981 Mil.
Gross Profit was ₹7,564 Mil.
Total Current Assets was ₹8,962 Mil.
Total Assets was ₹17,007 Mil.
Property, Plant and Equipment(Net PPE) was ₹7,865 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹536 Mil.
Selling, General, & Admin. Expense(SGA) was ₹442 Mil.
Total Current Liabilities was ₹1,422 Mil.
Long-Term Debt & Capital Lease Obligation was ₹19 Mil.
Net Income was ₹3,081 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹2,655 Mil.
Total Receivables was ₹3,121 Mil.
Revenue was ₹8,306 Mil.
Gross Profit was ₹6,336 Mil.
Total Current Assets was ₹7,277 Mil.
Total Assets was ₹15,140 Mil.
Property, Plant and Equipment(Net PPE) was ₹7,655 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹540 Mil.
Selling, General, & Admin. Expense(SGA) was ₹342 Mil.
Total Current Liabilities was ₹1,918 Mil.
Long-Term Debt & Capital Lease Obligation was ₹64 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3684.928 / 9980.573) / (3121.125 / 8306.322)
=0.36921 / 0.375753
=0.9826

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6335.655 / 8306.322) / (7564.473 / 9980.573)
=0.762751 / 0.75792
=1.0064

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8962.311 + 7864.785) / 17007.085) / (1 - (7277.001 + 7654.796) / 15139.818)
=0.010583 / 0.01374
=0.7702

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9980.573 / 8306.322
=1.2016

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(540.324 / (540.324 + 7654.796)) / (535.915 / (535.915 + 7864.785))
=0.065932 / 0.063794
=1.0335

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(442.383 / 9980.573) / (342.004 / 8306.322)
=0.044324 / 0.041174
=1.0765

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18.87 + 1421.554) / 17007.085) / ((63.994 + 1918.443) / 15139.818)
=0.084696 / 0.130942
=0.6468

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3081.032 - 0 - 2654.671) / 17007.085
=0.02507

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Concord Biotech has a M-score of -2.18 suggests that the company is unlikely to be a manipulator.


Concord Biotech Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Biotech Business Description

Traded in Other Exchanges
Address
Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines